Clinical trials: R/R AML
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with…
- Trial name
- NCT04203316
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 28 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- AUGMENT-101 (NCT04065399)
- Testing
- revumenib, cobicistat
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 447 people
- Sponsor
- Syndax Pharmaceuticals
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory…
- Trial name
- NCT07355335
- Testing
- Ziftomenib, Mezigdomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Donor lymphocyte infusion (DLI) based on minimal residual disease (MRD) has been widely adopted worldwide to enhance the graft-versus-leukemia effect following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT07319793
- Testing
- Prophylactic DLI, Preemptive DLI
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Relapsed/Refractory AML
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive.
- Trial name
- NCT03631576
- Testing
- CD123/CLL1 CAR-T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Medical University
Acute Myeloid Leukemia
CAV Regimen for R/R AML
This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT05657639
- Testing
- CAV Regimen, MEC Regimen
- Where
- China
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed/Refractory Acute Myeloid Leukemia
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.
- Trial name
- NCT05518357
- Testing
- LILRB4 STAR-T
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
MDS, AML
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface.
- Trial name
- NCT07131085
- Testing
- Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX)
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Relapsed or Refractory Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Acute myeloid leukemia (AML) is one of the hematologic malignancies, for which patients typically undergo chemotherapy to achieve complete remission.
- Trial name
- NCT06879847
- Testing
- Salvage Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neoplasms, Hematologic Neoplasms
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05907603
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Kai Lin Xu，MD
AML
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
This is an open label, phase I study to assess the safety and efficacy of CLL1+CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia
- Trial name
- NCT05467254
- Testing
- CLL1+CD33 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
AML
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
This is an open label, phase I study to assess the safety and efficacy of CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia
- Trial name
- NCT05473221
- Testing
- CD33 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
AML
NKG2D CAR-NK & r/rAML
This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
- Trial name
- NCT05734898
- Testing
- NKG2D CAR-NK
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia in Children
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
Acute myeloid leukemia (AML) accounts for about 15% to 20% of childhood leukemia, but the death rate accounts for about 50%. About 20-30% of children with AML did not achieve complete response (CR) after 2 induction treatments…
- Trial name
- NCT06233526
- Testing
- Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Hematopoietic System--Cancer
Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML
No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML）patients.
- Trial name
- NCT03654703
- Testing
- Cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Research Institute of Pediatrics
Leukemia, Acute Myeloid Leukemia
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A subset of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) harbor rearrangements of the MLL gene, which are detected either by cytogenetic or fluorescent in situ hybridization evaluation at the…
- Conditions
- Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Leukemias
- Trial name
- NCT02141828
- Testing
- EPZ-5676
- Where
- 9 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL)
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT04872595
- Testing
- Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Background: Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
- Conditions
- Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
- Trial name
- NCT02390752
- Testing
- TURALIO(R)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04762485
- Testing
- Humanized CD7 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University